Open in interactive viewer → charts, metric popovers & call review

HeartBeam Wins the FDA Argument and Loses the Commercial One

A 510(k) pathway, Breakthrough designation and pivotal data landed in a quarter where the concierge-subscription story quietly vanished — and the stock fell 35% into a December delisting deadline.
BEAT · Earnings Call · 2026-11-12

Two Companies, One Ticker

HeartBeam entered Q3 as a company selling a $750-a-year cardiac subscription into high-end concierge practices in two coastal geographies. It exited Q3 as a company selling an FDA argument. Those are different businesses, with different investors, and the tape has already voted on which one it thinks is being funded. The share price sits roughly 40% below its mid-July high of $0.66 and down about 35% over the last ninety trading days, per the price tape; from the 2022 peak of $5.94 it is a 93% drawdown. Nothing in the quarter's clinical news explains that. What explains it is the other half of the call.

The Milestones Are Real

On the regulatory side, management delivered more in 90 days than it had in the prior year. The FDA agreed to a heart attack assessment 510(k) rather than a De Novo — a materially shorter road — on top of Breakthrough Device Designation and admission to the TAP program, which is what gets a small company into a room with CMS and payers early. The ALIGN-ACS readout at TCT 2026 was the substance behind it: 132 emergency-department patients in Belgrade, where the patient-recorded device matched the standard 12 lead ECG. “HeartBeam showed higher specificity at 81.8% compared with 71.4% for the standard 12-lead ECG, with comparable sensitivity of 60.2% compared with 63.0%.” — Branislav Vajdic, Chief Medical Officer · 2026-11-12 Equal area under the curve, better reader agreement (Fleiss' kappa 0.73 versus 0.54), and every patient able to capture a recording unaided. Add HEADSTART-ACS in Indonesia — 486 patients enrolled ahead of schedule, more than 600 patients of cumulative clinical evidence — and the U.S. pivotal trial design is now a scaled-up ALIGN-ACS: roughly 300 patients, 8–10 centers, first enrollment plausibly before year-end, completion mid-2027. Finalizing the pivotal study design this quarter is the next hard checkpoint.

What Management Stopped Saying

Now the part that matters more. For four straight calls, HeartBeam's commercial narrative was the concierge channel: anchor accounts, flagship account depth, Southern California and South Florida territories, and a breakeven math built on patient counts. In August, the CFO was explicit about it being the near-term scorecard: “We want to get through Q3 and really start to see the orders come in and roll this out to start to provide those metrics... we've told the market historically it's about 30,000 patients to get to break even or it's cash flow positive.” — Tim Cruickshank, CFO · 2026-08-13 Q3 came. The orders metric did not. The Chief Commercial Officer who owned that plan is absent from this call entirely, the CEO who framed the strategy has been replaced in the seat by Executive Chairman Richard Ferrari, and the founder has been re-titled Chief Medical Officer. The keyword record confirms the deletion rather than a mere de-emphasis: concierge practice, Southern California and South Florida all register as this quarter's sharpest decliners in the company's own momentum history, while TAP program and heart attack assessment spike to the top. That is a management team changing the subject, and the keywords caught it. Asked directly whether the already-cleared arrhythmia product could be monetized, Ferrari did not spin:

Our focus, as you've heard us say before, with the arrhythmia detection right now, monetizing it in a large way is -- just simply isn't the focus... revenue generated from commercialization is just being modest, and we're testing the market and trying to understand reimbursement.

Richard Ferrari, Chief Executive Officer · 2026-11-12
That is an honest answer and a strategically enormous one. It converts HeartBeam from a company with a small but growing revenue line into a pure regulatory binary.

The Cash Math Meets the Calendar

The financial discipline is the genuinely impressive part of the quarter, and it is what buys the pivot credibility. Operating expenses fell to $3.5 million, down 35% year over year; net loss narrowed to $3.0 million from $5.3 million; operating cash burn of $2.6 million was down 23% sequentially. R&D spending is down roughly 30% year over year, and the operating loss has plateaued near $5 million a quarter for three straight quarters. Full-year operating outflow guidance was cut to $12–12.5 million from under $14 million. But the balance sheet is where the story bites. Cash was $6.1 million at September 30; roughly $4 million of net ATM proceeds since quarter-end gives a pro forma $10.1 million. That is about 2.6 quarters of runway, up from 1.5 the prior quarter. At a $2.5 million quarterly pace, the money runs out around mid-2027 — the exact window in which the pivotal trial is supposed to finish. And the clock that no one on the call wanted to dwell on: the December 28 NASDAQ minimum bid compliance date, with the shares well under a dollar. “We're in communication with NASDAQ and in good standing. So at this point, we're fully expecting an extension, which would be another 180 days.” — Timothy Cruickshank, Chief Financial Officer · 2026-11-12 A 180-day extension takes you to late June 2027. The cash takes you to roughly then. Both clocks point at the same week, which is presumably why cash runway and capital efficiency were the only commercial-adjacent phrases management allowed itself. Note too that stock-based compensation add-back was about $2 million against a $3 million net loss.

The Market's Weather Versus This Stock's Weather

There is real confluence here, just not the helpful kind. Expedited FDA pathways were among the market's live themes this quarter — review process ranked near the top of the global keyword board in Q3, and the basket of Fast Track designation names has traded up double digits over 90 days. Regulatory optionality is being paid for in the market. It is not being paid for in HeartBeam, because HeartBeam's version of it requires a financing before the option matures. The AI angle is the same story in miniature: an internal model beating physician readers by 12 percentage points on all heart attacks and 19 on NSTEMI is a genuinely interesting arrhythmia AI model-adjacent datapoint — but it is internal, unreviewed, uncleared, and management labelled it as such. It is a free call option, not a valuation input.

Bottom Line

Ferrari's framing is that between now and the end of 2027 there is “very little risk in our path going forward. It is pure execution” — Richard Ferrari, Chief Executive Officer · 2026-11-12 — and on the regulatory axis, the quarter supports him. The risk is not execution. The risk is that a $22 million company with two and a half quarters of cash and a sub-dollar share price must bridge to a mid-2027 pivotal readout in a market that has stopped rewarding the only revenue line it has. The concession buried in the Q&A — that commercialization "just simply isn't the focus" — is worth more to an investor than any of the four milestones, because it tells you exactly what you now own: not a subscription business with a device, but a pure execution wager on one trial, one clearance, and one financing that has to happen first.